InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

Current share price for TLX : $16.450 0.28 (1.67%)+

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,589 TLX66 Meets Study Objectives in Patients with AL Amyloidosis 25 May 2021 8:40AM $4.000 $16.450 risen by 311.25%
$5,589 1st Patient Dosed in Japanese Prostate Cancer Imaging Study 25 May 2021 8:22AM $4.000 $16.450 risen by 311.25%
$5,589 German Distribution Agreement with Eckert and Ziegler 18 May 2021 8:21AM $4.150 $16.450 risen by 296.39%
$5,589 App 3Y - issue of CEO options following Shareholder approval 12 May 2021 2:17PM $3.670 $16.450 risen by 348.23%
$5,589 AGM Results of Meeting 12 May 2021 1:42PM $3.710 $16.450 risen by 343.40%
$5,589 CEOs Address to AGM 12 May 2021 10:33AM $3.860 $16.450 risen by 326.17%
$5,589 Chairmans Address to AGM 12 May 2021 10:31AM $3.860 $16.450 risen by 326.17%
$5,589 Phase III Prostate Cancer Therapy Clinical Trial Commences 10 May 2021 8:21AM $3.940 $16.450 risen by 317.51%
$5,589 Executive Leadership Appointments and Establishment of APAC 3 May 2021 8:08AM $3.740 $16.450 risen by 339.84%
$5,589 Telix Appoints Mr Richard Valeix as EMEA President 3 May 2021 8:08AM $3.740 $16.450 risen by 339.84%
$5,589 Manufacturing Agreement with Global Medical Solutions 27 Apr 2021 8:21AM $3.800 $16.450 risen by 332.89%
$5,589 Activities Report and App 4C for quarter ended 31 March 2021 22 Apr 2021 8:24AM $3.960 $16.450 risen by 315.40%
$5,589 Japanese Renal Cancer Imaging Trial Meets Study Objectives 21 Apr 2021 8:24AM $3.910 $16.450 risen by 320.72%
$5,589 Launch of International NOBLE Registry for SPECT Imaging 19 Apr 2021 8:23AM $3.970 $16.450 risen by 314.36%
$5,589 TGA commences priority evaluation process for Illuccix 14 Apr 2021 8:20AM $4.040 $16.450 risen by 307.18%
$5,589 AGM Notice of Meeting and Explanatory Memorandum 12 Apr 2021 8:18AM $4.250 $16.450 risen by 287.06%
$5,589 Agreement with GRAM for commercial manufacture of Illucix 31 Mar 2021 8:24AM $4.330 $16.450 risen by 279.91%
$5,589 Cleansing Notice - shares issued upon exercise of options 26 Mar 2021 8:24AM $4.500 $16.450 risen by 265.56%
$5,589 App 2A - quotation of shares issued upon exercise of options 26 Mar 2021 8:23AM $4.500 $16.450 risen by 265.56%
$5,589 Global Agreements with ITM for Lutetium-177 Supply 18 Mar 2021 8:24AM $4.210 $16.450 risen by 290.74%
$5,589 S&P DJI Announces March 2021 Quarterly Rebalance 12 Mar 2021 5:02PM $3.860 $16.450 risen by 326.17%
$5,589 Cleansing Notice - issue of shares upon exercise of options 9 Mar 2021 8:25AM $3.560 $16.450 risen by 362.08%
$5,589 App 2A - quotation of shares on exercise of options 9 Mar 2021 8:25AM $3.560 $16.450 risen by 362.08%
$5,589 Cleansing Notice - issue of shares upon exercise of options 2 Mar 2021 10:37AM $4.070 $16.450 risen by 304.18%
$5,589 App 2A - quotation of shares on exercise of options 2 Mar 2021 10:36AM $4.070 $16.450 risen by 304.18%

626 - 650 of 948 results

Page 26 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.